Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have earned a consensus recommendation of “Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.60.

A number of research analysts recently issued reports on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $9.00 to $12.00 in a research note on Monday. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, Piper Sandler lifted their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total value of $501,345.90. Following the sale, the director now directly owns 1,968,886 shares in the company, valued at $15,770,776.86. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 160,000 shares of company stock worth $1,292,000. 26.56% of the stock is currently owned by insiders.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $52,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Amneal Pharmaceuticals by 45.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company’s stock valued at $2,522,000 after buying an additional 99,866 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Amneal Pharmaceuticals by 540.5% in the fourth quarter. Squarepoint Ops LLC now owns 124,744 shares of the company’s stock valued at $988,000 after buying an additional 105,268 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Amneal Pharmaceuticals by 97.9% in the fourth quarter. ProShare Advisors LLC now owns 59,493 shares of the company’s stock valued at $471,000 after buying an additional 29,424 shares in the last quarter. Finally, Quantedge Capital Pte Ltd purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $598,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Down 0.6 %

NASDAQ:AMRX opened at $8.38 on Friday. The stock’s 50 day moving average price is $8.08 and its 200 day moving average price is $8.31. The company has a market capitalization of $2.60 billion, a PE ratio of -12.32 and a beta of 1.10. Amneal Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $9.48.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.